• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

关于1型糖尿病患者使用自动胰岛素输送系统的真实世界证据综述

A Review of Real-World Evidence About the Use of Automated Insulin Delivery Systems in People With Type 1 Diabetes.

作者信息

Gera Sonia, Iyer Jaisree, Meighan Seema, March Christine A, Marks Brynn E

机构信息

Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

Division of Pediatric Endocrinology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.

出版信息

Endocr Pract. 2025 Jun 10. doi: 10.1016/j.eprac.2025.06.004.

DOI:10.1016/j.eprac.2025.06.004
PMID:40505729
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12229220/
Abstract

INTRODUCTION

Automated insulin delivery systems (AID) have revolutionized type 1 diabetes (T1D) management. Guidelines support offering AID to all people with T1D and engaging in shared decision making when choosing among the available AID systems.

RESULTS

In clinical trials, AID has been shown to improve glycemic control and reduce hypoglycemia while also improving quality of life. However, participants in clinical trials do not accurately reflect the entire T1D population and outcomes from these controlled may not generalize to clinical care. A growing body of real-world evidence seeks to understand the effect of AID systems on glycemia and person-reported outcome measures in real-world populations. These real-world studies highlight the effect of differences in engagement with AID, including time in automated mode and boluses per day, considerations about AID system selection, and approaches to educate people with T1D.

CONCLUSION

In this review, we compare glycemic and person reported outcomes in clinical trials and the real-world studies, with consideration of the effects of different systems according to user characteristics. We also review the current state of device selection and education for people with diabetes, their caregivers, and clinicians. Lastly, we summarize key findings across AID systems and opportunities for further research.

摘要

引言

自动胰岛素输送系统(AID)彻底改变了1型糖尿病(T1D)的管理方式。指南支持为所有T1D患者提供AID,并在现有AID系统中进行选择时参与共同决策。

结果

在临床试验中,AID已被证明可改善血糖控制、降低低血糖风险,同时还能提高生活质量。然而,临床试验的参与者并不能准确反映整个T1D人群,这些对照试验的结果可能无法推广到临床护理中。越来越多的真实世界证据试图了解AID系统对真实世界人群血糖和患者报告结局指标的影响。这些真实世界研究突出了使用AID的差异所产生的影响,包括自动模式下的时间和每日大剂量注射次数、AID系统选择的考量因素,以及对T1D患者的教育方法。

结论

在本综述中,我们比较了临床试验和真实世界研究中的血糖及患者报告结局,并根据用户特征考虑了不同系统的影响。我们还回顾了糖尿病患者、其护理人员和临床医生在设备选择和教育方面的现状。最后,我们总结了AID系统的关键发现以及进一步研究的机会。

相似文献

1
A Review of Real-World Evidence About the Use of Automated Insulin Delivery Systems in People With Type 1 Diabetes.关于1型糖尿病患者使用自动胰岛素输送系统的真实世界证据综述
Endocr Pract. 2025 Jun 10. doi: 10.1016/j.eprac.2025.06.004.
2
Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling.用于管理1型糖尿病患者血糖水平的混合闭环系统:系统评价与经济建模
Health Technol Assess. 2024 Dec;28(80):1-190. doi: 10.3310/JYPL3536.
3
Automated Insulin Delivery Systems for Treatment of Type 1 Diabetes: Strategies for Optimal Performance.用于治疗1型糖尿病的自动胰岛素输送系统:实现最佳性能的策略
Horm Res Paediatr. 2025 Jan 24:1-13. doi: 10.1159/000543654.
4
Methods for insulin delivery and glucose monitoring in diabetes: summary of a comparative effectiveness review.糖尿病胰岛素给药与血糖监测方法:一项比较有效性综述的总结
J Manag Care Pharm. 2012 Aug;18(6 Suppl):S1-17. doi: 10.18553/jmcp.2012.18.s6-A.1.
5
Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems.自动胰岛素输送系统的研究空白、挑战与机遇
Diabetes Technol Ther. 2025 Jul;27(S3):S60-S71. doi: 10.1089/dia.2025.0129.
6
Does the OP5 Automated Insulin Delivery System Close the Gap in Glycemic Control Between White and Black Youth with Type 1 Diabetes?OP5自动胰岛素输送系统能否缩小1型糖尿病白人青年和黑人青年在血糖控制方面的差距?
Diabetes Technol Ther. 2025 Jun;27(6):469-478. doi: 10.1089/dia.2024.0612.
7
Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems.自动胰岛素输送系统的研究空白、挑战与机遇
J Diabetes Sci Technol. 2025 Jul;19(4):937-949. doi: 10.1177/19322968251338754. Epub 2025 Jul 1.
8
Glycaemic control in labour with diabetes: GILD, a scoping study.糖尿病产妇分娩期间的血糖控制:GILD,一项范围界定研究。
Health Technol Assess. 2025 Aug;29(41):1-150. doi: 10.3310/KHGD2761.
9
The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes.胰岛素治疗的卫生经济学:我们如何应对不断增长的需求、成本、不平等现象以及实现最佳治疗效果的障碍。
Diabetes Obes Metab. 2025 Jul;27 Suppl 5(Suppl 5):24-35. doi: 10.1111/dom.16488. Epub 2025 Jun 4.
10
Registration and Real-Life Studies on Automated Insulin Delivery Systems.自动胰岛素给药系统的注册及真实世界研究
Diabetes Technol Ther. 2025 Jul;27(S3):S48-S59. doi: 10.1089/dia.2025.0130.

本文引用的文献

1
Does the OP5 Automated Insulin Delivery System Close the Gap in Glycemic Control Between White and Black Youth with Type 1 Diabetes?OP5自动胰岛素输送系统能否缩小1型糖尿病白人青年和黑人青年在血糖控制方面的差距?
Diabetes Technol Ther. 2025 Jun;27(6):469-478. doi: 10.1089/dia.2024.0612.
2
One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study.Tandem Control-IQ技术对1型糖尿病成人患者血糖管理及患者自我报告结局的一年真实世界获益:一项前瞻性观察性队列研究
Diabetologia. 2025 May;68(5):948-960. doi: 10.1007/s00125-025-06366-x. Epub 2025 Feb 11.
3
Changes in 90-Day Time in Range Among Youth with Type 1 Diabetes Initiating Different Automated Insulin Delivery Systems.1型糖尿病青少年启动不同自动胰岛素给药系统后90天血糖在目标范围内时间的变化。
J Clin Endocrinol Metab. 2025 Jan 15. doi: 10.1210/clinem/dgaf006.
4
Towards standardization of person-reported outcomes (PROs) in pediatric diabetes research: A consensus report.迈向儿科糖尿病研究中患者报告结局(PROs)的标准化:一份共识报告。
Diabet Med. 2025 Mar;42(3):e15484. doi: 10.1111/dme.15484. Epub 2024 Dec 17.
5
International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Diabetes Technologies - Insulin Delivery.国际儿童和青少年糖尿病学会2024年临床实践共识指南:糖尿病技术 - 胰岛素输注
Horm Res Paediatr. 2024;97(6):636-662. doi: 10.1159/000543034. Epub 2024 Dec 10.
6
14. Children and Adolescents: Standards of Care in Diabetes-2025.14. 儿童和青少年:2025年糖尿病照护标准
Diabetes Care. 2025 Jan 1;48(Supplement_1):S283-S305. doi: 10.2337/dc25-S014.
7
7. Diabetes Technology: Standards of Care in Diabetes-2025.7. 糖尿病技术:2025年糖尿病照护标准
Diabetes Care. 2025 Jan 1;48(Supplement_1):S146-S166. doi: 10.2337/dc25-S007.
8
Treatment regimens and glycaemic outcomes in more than 100 000 children with type 1 diabetes (2013-22): a longitudinal analysis of data from paediatric diabetes registries.10万多名1型糖尿病儿童的治疗方案与血糖结果(2013 - 2022年):来自儿科糖尿病登记处数据的纵向分析
Lancet Diabetes Endocrinol. 2025 Jan;13(1):47-56. doi: 10.1016/S2213-8587(24)00279-1. Epub 2024 Nov 29.
9
Ketone Management in Pediatric Diabetes Centers in the USA: Current Practices and a Call for Improved Standardization.美国儿科糖尿病中心的酮体管理:当前实践及对改进标准化的呼吁。
Horm Res Paediatr. 2024 Oct 15:1-9. doi: 10.1159/000541430.
10
Psychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes.1 型糖尿病患儿照料者使用 Omnipod® 5 自动化胰岛素输送系统的心理社会结局。
Diabetes Obes Metab. 2024 Dec;26(12):5569-5579. doi: 10.1111/dom.15906. Epub 2024 Sep 20.